Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Ex vivo and In vivo Model Advancements for Airway Stent Design Optimization

Award Number: R21EB036775
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/05/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Ex vivo and In vivo Model Advancements for Airway Stent Design Optimization - PROJECT SUMMARY Tracheobronchomalacia is a rare disease involving excessive airway collapse due to weakening of the airway walls. It is diagnosed in 13% of adults and 30% of children who undergo bronchoscopy for respiratory distress. The disease is characterized by the percentage collapse and collapse-morphology in the weakened airway segment. The collapse-morphology can vary depending on the relative anatomical region(s) of tissue weakening. Mild to moderate Tracheobronchomalacia can be treated non-invasively via positive pressure ventilation. Positive pressure ventilation, while noninvasive, requires the patient to be attached continuously to a pressure generating device for effective treatment. Severe Tracheobronchomalacia usually requires surgical intervention that involves attaching supportive materials outside the trachea that thwarts regional collapse. Surgical interventions are complex and require long post-operative recovery. Airway stents provide a simple, economical and minimally invasive treatment mode. Unfortunately, available stents are avoided or only implanted for monitored short periods due to stent-associated complications of excessive granulation tissue formation and mucus plugging resulting from the foreign body reaction against the implanted stent. Stent physical characteristics play a significant role in inducing excessive granulation tissue formation and mucostasis. The stent physical characteristics which include the stent material, geometry and size, need to be optimized at the design and development stage to minimize the physical impact during implantation. Existing benchtop and animal models can neither reliably generate the grades and morphologies of Tracheobronchomalacia, nor do they possess the granularity needed to perform design optimization. In this proposal we will establish new research tools and protocols that will substantially advance the stent design process and propel the development of viable airway stents. We present the first benchtop platform for rapid stent testing capable of generating specific grades and morphologies of Tracheobronchomalacia and accurately simulate dynamic airway collapse. Our system evaluates stent effectiveness in the clinically relevant parameter of airway lumen cross-sectional area. Furthermore, the platform can map the device-to-airway contact force distribution during dynamic airway collapse. In aim 1, we will first establish the protocols for reliably generating the clinical grades of Tracheobronchomalacia. Next, we will evaluate the performance of helical and axial stent designs of varying geometric feature values. This will determine the geometric parameter for each stent design for treating Tracheobronchomalacia using minimum material and contact forces. In aim 2, we will study the effect of stent geometry and oversizing on the spatial distribution and severity of granulation tissue formation and mucostasis. At the conclusion of experiments from both aims, we will attempt to establish a relationship between the spatial characteristics of granulation tissue recorded from the animal study and the benchtop contact forces. This will enable assessing stent designs prone to granulation tissue complications before testing stents in animals.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $267,000 )
2026	2026	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	5/22/2026	NON-COMPETING CONTINUATION	$267,000
														Subtotal = $267,000

Issue Date FY: 2025 ( Subtotal = $222,500 )
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	7/4/2025	NEW	$222,500
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	1	8/26/2025	NEW	$0
														Subtotal = $222,500

Grand Total All Awards = $489,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ex vivo and In vivo Model Advancements for Airway Stent Design Optimization

Award Number: R21EB036775

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/05/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer